WCIRDC meeting to highlight new recommendations for cardiometabolic practice

December 01, 2021

3 minutes read

Source / information

Published by:

Disclosure:
Handelsman chairs the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected].

Back to Healio

Experts from the fields of diabetes, heart and metabolic diseases and obesity will discuss new research results and practical recommendations at the 19th World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases.

The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), a multidisciplinary CME program for the treatment of obesity, diabetes, lipids, high blood pressure, chronic kidney disease, cardiovascular disease, heart failure, non-alcoholic fatty liver (NAFLD) and more, takes place from Thursday to Saturday. After the 2020 congress has gone virtual due to the COVID-19 pandemic, this year’s congress will have a hybrid format, with the meetings taking place in person at the Hilton Universal City in Los Angeles and being streamed live online. All sessions of the conference will be available on demand for 90 days.

Source: Adobe Stock

Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, medical director and chief investigator of the Metabolic Institute of America in Tarzana, Calif., and chairman of the WCIRDC, said the conference was the only meeting of its size to include presentations on basic research and clinical care for all cardiorenal metabolic specialties. The motto of this year’s meeting is Exploring New Frontiers in Metabolism – Tomorrow’s Clinical Science Today.

Yehuda Handelsman

“We want to see how the information we’ve gathered this year will affect how we treat our patients,” Handelsman told Healio. “How will some new findings from basic research ultimately find their place in future medical care? How does a drug like an SGLT2 inhibitor work, what does it do? We consider both basic science and translational science. “

WCIRDC brings together professionals, researchers, and clinicians from diverse disciplines to collaborate on scientific and management strategies in various areas of cardiometabolic health. The program will include updates on research and treatment recommendations for obesity, diabetes, insulin resistance, COVID-19, dyslipidemia, NAFLD, atherosclerotic CVD, heart failure, CRF, pediatric cardiorenal metabolic care, hormones, atherosclerosis and more.

One of the highlights of this year’s congress is a unique session in which experts from various fields present recommendations for interdisciplinary practices. The recommendations come from the workshop Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases, which took place in Dallas in June.

“Traditionally, guidelines and best practice recommendations have been provided by medical societies,” said Handelsman. “These medical societies focus on individual diseases, but today we are looking at the cardiorenal metabolic patient who may also have multiple morbidities. What we have created is something that everyone – specialist and general practitioner – can follow. “

Further highlights of this year’s conference:

Pediatric care will be the focus of a session on Thursday at 2:10 p.m. PST. Andrew Moran, MD, MPH, will talk about the benefits of early lipid lowering interventions in preventing cardiovascular disease later on, Sonia Caprio, MD, will discuss prediabetes and NAFLD in pediatric obesity and Phil Zeitler, MD, PhD, will present results of the TODAY study on the long-term complications of type 2 diabetes in adolescence.

A joint meeting with Metabolism magazine will be on Friday at 8:15 am PST. With Dale Abel, MD, PhD, Michael A. Hill, PhD, and Theodoros Kelesidis, MDPhD, the session will focus on the effects of insulin, diabetes and the heart, the cardiovascular effects and the therapeutic potential of novel antidiabetic drugs, and the development of drugs for cardiovascular diseases.

A session will be held on Saturday at 8:15 am PST with presentations on the past, present, and future of diabetes care. Jay S. Skyler, MD, looks back on the past 100 years since the discovery of insulin. Peter J. Grant, MD, will discuss the long-term treatment of hyperglycemia and Jennifer Green, MD, will talk about early combination therapy for diabetes and its effects on comorbidities. Julio Rosenstock, MD, will conclude the session with a presentation on reversing type 2 diabetes from day 1.

The Gerald Reaven Distinguished Leader in Insulin Resistance Award 2021 is presented to Samuel Klein, MD, on Saturday at 10:35 a.m. PST. Klein’s talk will focus on why obesity causes type 2 diabetes.

The congress will also include a poster hall, oral abstract presentations and an exhibition hall. Each day ends with a recap session where attendees can ask questions to several of the speakers featured on that day.

Healio will report on the 19th World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, including reports on the sessions and researchers’ perspectives. More information about the conference and how to register can be found at www.wcir.org.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected].

Back to Healio

World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases